Administration of Type 2 Diabetes Mellitus: Initiating Insulin Therapy

0
0
2660 days ago, 1004 views
PowerPoint PPT Presentation

Presentation Transcript

Slide 1

Administration of Type 2 Diabetes Mellitus: Initiating Insulin Therapy Med-Peds Continuity Clinic Baylor College of Medicine Anoop Agrawal, M.D.

Slide 2

Case One 50 yo male with determined to have Type 2 diabetes three months back. He has been on Metformin 1000mg offer since determination. A1C was 8.7 at time of analysis. Today: Hgb A1c is 7.3 with a FBS of 165 mg/dl You are sure he has been agreeable with his treatment. What is your next stride?

Slide 3

Case One A. No adjustment in treatment, recheck A1c in 3 months B. Begin Glyburide 5mg offer C. Begin Actos 30mg day by day D. Begin NPH 10 units qhs

Slide 4

Case One A. No adjustment in treatment, recheck A1c in 3 months B. Begin Glyburide 5mg offer C. Begin Actos 30mg every day D. Begin NPH 10 units qhs B, C or D - every single worthy decision

Slide 5

ADA Diabetes Algorithm Diabetes Care, Vol 6, Number 8, August 2006

Slide 6

Case One - Clinician Inertia Initiate treatment with metformin and rethink A1c following 3 months. On the off chance that objective of ≤7% not met, then propel treatment. It is not important to titrate a solution to maximal dose before including another specialist. Going above a large portion of the maximum prescribed measurement of a sulfonylurea gives minimal extra advantage. (i.e. glyburide 5mg offer is adequate) Similarly, expanding metformin from 2000mg to max of 2550 does little to profit.

Slide 7

Case One - Clinical Inertia A study out of Kaiser Permanente in California took a gander at what number of patients moved to next level of treatment when A1C was more than 8% On sulfonlyurea - 35% On metformin - 44% On two oral operators - 18% all in all, patients put in 5 years with A1C more than 8% preceding choice was made to include insulin!

Slide 8

Barriers to Starting Insulin: Patient Driven Fear of needles/infusions and agony Fear of hypoglycemia Belief that once one begins insulin, they will soon bite the dust Belief that beginning insulin implies the "ailment has won" Fear of insulin incited by the supplier "in the event that you don't begin doing X, I must put you on insulin"

Slide 9

Barriers to Starting Insulin: Provider Driven Unsure how to begin and how to alter Fear of advancing vascular difficulties Belief that patient consistence will be unfavorably influenced Fear of patient dismissal Concern for actuating reactions (hypoglycemia, weight pick up)

Slide 10

Decline in β-cell work: UKPDS 25-30% introductory non-responders to OHA 5-20% come up short every year by 10-15 yrs, ~100% OHA disappointment

Slide 11

Oral Hypoglycemic Agents: MOA and Efficacy

Slide 12

Oral Agents Sulfonylurea viability decreases with the dynamic lessening β-cell work. Metformin and Glitazones keep on providing some advantage over the span of the illness particularly those with insulin resistance. With a specific end goal to hold fast to ADA and ACE treatment objectives, doctors ought to consider starting insulin treatment at the primary indication of poor reaction to oral specialists. When all is said in done, patients with A1c >10% should be on insulin.

Slide 13

Insulins and Duration of Action

Slide 14

Patient is on glucovance 2.5/500 2 tabs po offer. He has had DM II for a long time. What is your next game-plan? Start insulin treatment with BIDS treatment - daytime sulfonylurea and evening time NPH insulin

Slide 15

Case Two 45 yo female with Type 2 diabetes for as far back as 5 years. Current drugs: Glipizide 10mg day by day and Metformin 1000mg offer Today: Hgb A1c is 8.5 with a FBS of 150-220 mg/dl over recent months in her log book. What is your next stride?

Slide 16

Case Two A. Add on a TZD operator (i.e. Actos) B. Add on a DPP IV specialist (i.e. Januvia) C. Add on a long acting insulin at sleep time D. Stop oral medications and begin insulin basal-bolus treatment

Slide 17

Case Two A. Add on a TZD specialist (i.e. Actos) B. Add on a DPP IV operator (i.e. Januvia) C. Add on a long acting insulin at sleep time D. Stop oral medications and begin insulin basal-bolus treatment

Slide 18

Case Two Add basal insulin!! Try not to include a third oral antidiabetic operator! Why? Comprehend the regular course of diabetes, i.e. the dynamic decrease of insulin generation with time (beta-cell misfortune) Understand the relationship amongst insulin and hepatic glucose creation, and its impact on fasting glucose.

Slide 19

Bedtime insulin/Daytime Sulfonylurea (BIDS) General dependable guidelines: Start with 10 units NPH qhs Administration is for the most part between 10 pm and midnight.

Slide 20

Case Two First, concentrate on getting fasting plasma glucose to 70-130 mg/dl. QHS insulin will smother hepatic glucose generation at overnight, diminishing FPG. In the Treat-to-Target Trial, the expansion of evening time basal insulin to oral operators brought A1C from 8.6% down to 7% in ~10 weeks. The concentrate likewise looked at NPH versus glargine and found no contrast amongst NPH and glargine in accomplishing A1C diminishment.

Slide 21

Case Two - QHS insulin when all is said in done, the beginning measurements at sleep time is less imperative than having a titration calculation. Normally, begin at 10 units qhs or 0.1 to 0.2 units for every kg. Most patients will wind up requiring 0.5 to 1.0 units for each kg. Titration should be possible each 2-3 days by the patient until FPG comes to close to 100-120 mg/dl.

Slide 22

Titration of sleep time insulin

Slide 23

Initiating Basal Insulin Algorithm Once FPG at 70-130 mg/dl A1c still >7% then begin surveying pre-supper sugars. Pre-lunch high: include Reg at breakfast Pre-supper high: include NPH at breakfast Pre-bed high: include Reg at supper Text Diabetes Care, Vol 6, Number 8, August 2006

Slide 24

Insulin + Oral Agents Pros Decreased insulin dosage Potential for less hypoglycemia Less serious insulin regimens Cons Increased number of meds – diminished consistence Potential for medication cooperations Potentially more exorbitant

Slide 25

Case Three: A 56 yo male with glyburide 5mg day by day, metformin 1gm offer and NPH insulin 35 units qHS. His A1C is 8%. The following is his glucose log. What is your next game-plan?

Slide 26

Case Three A. Include Actos 45mg day by day B. Include NPH in the AM and proceed qHS C. Begin standard insulin qam and qpm, alongside NPH qam and qpm; stop glyburide D. Begin Lantus once day by day, stop NPH; proceed with oral drugs.

Slide 27

Case Three A. Include Actos 45mg day by day B. Include NPH in the AM and proceed qHS C. Begin customary insulin qam and qpm, alongside NPH qam and qpm; stop glyburide D. Begin Lantus once every day, stop NPH; proceed with oral medicines.

Slide 28

Case Three As A1c methodologies target levels (<8-8.5%), postprandial glucose contributes more than half to estimation of the A1c. Utilize basal insulin to accomplish quick decrease in A1c's more noteworthy than 8.5% However, to accomplish objective of 6.5-7% may require the expansion of prandial insulin.

Slide 29

ADA Diabetes Algorithm Diabetes Care, Vol 6, Number 8, August 2006

Slide 30

Options in basal Insulin Glargine set up of NPH Pros: convenience (once every day) 35% lower frequency of hypoglycemia Cons: model confinements/cost NPH similarly compelling in agreeable patients

Slide 31

Starting Insulin Only Normal day by day insulin emission is 0.5 to 0.7 u/kg/day Hence, beginning insulin measurements extend from 0.3 to 1.0 u/kg/day, with the normal being 0.5 to 0.8 u/kg/day. Figures picking 24 hour insulin needs: physical action level, weight, renal disappointment, coinciding ailment, dietary patterns

Slide 32

Calculating 24-hour insulin needs

Slide 33

Insulin Adjustments Ms. Smith is on NPH 40u/Reg 14u qam, Reg 10u preceding supper and NPH 30u qhs. She has reported numerous daytime and evening time scenes of hypoglycemia. You choose to change NPH to glargine. How would you change over NPH to glargine? 80% of NPH measurement = beginning glargine dosage

Slide 34

Other objectives for insulin treatment Patients who no longer have β-cell work require a Basal-Bolus Insulin Regimen , i.e. NPH offer/glargine qd consolidated with short acting insulin premeals. Premix insulins (70/30, 75/25) are more hard to modify and consequently less prevalent. Serves as a decent alternative for patients impervious to more than two infusions of insulin a day.

Slide 35

Common Questions How regularly ought to glucose be checked? At any rate as frequently as an infusion of insulin is given Can insulins be blended (in same syringe)? NOT with Glargine Always draw up Short Acting Insulin before halfway acting Remember: First draw up clear, then shady - short acting insulins are clear, long acting are shady (aside from glargine - is clear)

Slide 36

Common Questions What to do with insulin dosage when NPO? Proceed glargine at same dosage Skip Short Acting Insulin FBG level ought not fluctuate if the glargine measurements is right. On the off chance that utilizing NPH – pt ought to take half of dosage Skip SAI

Slide 37

New Insulin Therapies Exubera - breathed in insulin no favorable position over injectable insulin will require checking with PFTs Now off the market because of absence of utilization New quick acting specialists: glulisine (Apidra) New middle of the road to long acting (basal) insulin: detemir (Levemir)

Slide 38

Summary Oral operators have constrained adequacy which will wind down over a timeframe. Insulin start ought to be considered in any patient on two oral operators at greatest measurements and A1C more than 7%. Blend treatment of an oral operator with insulin is sheltered and successful. Picking and dosing an insulin plan ought to consider the patient's profile and way of life.

Slide 39

References Nathan, DM. et al. Administration of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care Aug 2006;29:1963-1972. Nelson SE, Palumbo PJ. Expansion of Insulin to Oral Therapy in Patients with Type 2 Diabetes. The American Journal of Medical Sciences May 2006;331:257-63. McMahon G, Dluhy RG. Goal to Treat - Initiating Insulin and the 4-T Study. New England Journal of Medicine Oct 07;357:1759-1761. Hirsch IB. Insulin Analogs. New England Journal of Medicine Jan 05;352:174-83.

SPONSORS